MAA for nivolumab is the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type. Bristol-Myers Squibb senior vice-president and head of Oncology Development
VVA results from the decrease in naturally occurring estrogen during menopause, resulting in thinning of the vaginal lining and an increase in vaginal pH levels. The Phase III
In May 2014, the companies have agreed on the development of MGD010, and the four new research programs are in addition to that product. Each of the four
Vitavis CEO Tim Tigner said Pruvin supports healthy metabolism resulting in numerous significant benefits to users. "Pruvin supports healthy metabolism resulting in numerous significant benefits to users," Tigner
The agreement also includes an additional contingent consideration of about $350m based on achievement of certain sales milestones The acquisition will give AMAG access to Lumara’s Makena, the
As part of the deal, Perrigo will receive an upfront payment in addition to multiple development-related milestone payments and royalties on any future sales derived from the portfolio.
The results, related to a secondary endpoint from the 250-patient trial, showed that 45% of patients treated with dabrafenib were still alive at two years compared to 32%
Earlier, Merrimack entered into an exclusive license and collaboration agreement with Baxter International for MM-398 outside of the US and Taiwan. In May 2011, PharmaEngine licensed the development,
SB623 is an allogeneic cell product derived from bone marrow stromal cells isolated from healthy donors, and is currently being developed by SanBio. Compared to autologous cell therapy,
ILUVIEN 0.19mg is a sustained release intravitreal implant approved in the US for the treatment of DME in patients who have been previously treated with a course of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.